AstraZeneca stock downgraded to Sell by Deutsche Bank on pipeline concerns
NegativeFinancial Markets

AstraZeneca's stock has been downgraded to 'Sell' by Deutsche Bank due to concerns over its drug pipeline. This decision reflects worries about the company's future growth potential and could impact investor confidence. The downgrade is significant as it highlights the challenges AstraZeneca faces in maintaining its market position, especially in a competitive pharmaceutical landscape.
— Curated by the World Pulse Now AI Editorial System